Provided by Tiger Trade Technology Pte. Ltd.

INVESCO PHARMACEUTICALS ETF

124.09
-0.6464-0.52%
Post-market: 124.090.00000.00%19:30 EDT
Volume:26.40K
Turnover:3.29M
Market Cap:542.27M
PE:6.43
High:125.99
Open:125.88
Low:124.09
Close:124.74
52wk High:131.68
52wk Low:90.01
Shares:4.37M
Float Shares:4.37M
Volume Ratio:0.78
T/O Rate:0.60%
Dividend:1.06
Dividend Rate:0.85%
EPS(TTM):19.29
EPS(LYR):21.73
ROE:23.89%
ROA:0.60%
PB:1.63
PE(LYR):5.71

Loading ...

Lilly is Bigger than Ever. Why Its Latest $2.9 Billion Immunology Deal Makes Sense.

Dow Jones
·
Aug 31

AbbVie to Present at Wells Fargo Healthcare Conference

Reuters
·
Aug 31

Abbott Launches the First and Only Ready-to-Feed Liquid Infant Formula Made with Whole Milk in the U.S. at Similar Price to Its Existing Similac Powdered Formula

THOMSON REUTERS
·
Aug 31

Eli Lilly's Psoriasis Drug Trial Shows Sustained Positive Results

Dow Jones
·
Aug 31

Lilly to Buy This Autoimmune Drugmaker for $2.9 Billion in Cash. What it Means for the Stock.

Dow Jones
·
Aug 31

Eli Lilly announces 52-week results from TOGETHER-PsO, TOGETHER-PsA

TIPRANKS
·
Aug 31

Eli Lilly - Taltz and Zepbound Lead to Deeper Improvements in Systemic Inflammation in Both Trials

THOMSON REUTERS
·
Aug 31

New Phase 3B Data on Lilly's Taltz (Ixekizumab) and Zepbound (Tirzepatide) Used Together Showed Improved and Durable Efficacy at One Year in Adults with Psoriatic Disease and Obesity

THOMSON REUTERS
·
Aug 31

Eli Lilly - Taltz and Zepbound Maintain or Improve Disease Activity at Week 52 Versus Taltz Alone

THOMSON REUTERS
·
Aug 31

Eli Lilly: Adverse Events in Participants Treated with Taltz and Zepbound Together were Generally Mild to Moderate

THOMSON REUTERS
·
Aug 31

Lilly to Acquire Merida Biosciences in Deal Worth up to USD 2.88 Billion

Reuters
·
Aug 31

Eli Lilly: Under Terms of Agreement, Lilly Will Acquire Merida and Pay up to $2.875 Bln in Cash

THOMSON REUTERS
·
Aug 31

Lilly to Acquire Merida Biosciences to Advance Treatments for Serious Autoimmune and Allergic Diseases

THOMSON REUTERS
·
Aug 31

Eli Lilly - Deal Expected to Close in Q4 2026 Subject to Regulatory Approvals

THOMSON REUTERS
·
Aug 31

Amgen Says Repatha Cuts Death Risk 20% in High-Risk Patients

MT Newswires Live
·
Aug 31

Amgen Repatha reduces risk of death in high-risk adults for first heart attack

TIPRANKS
·
Aug 31

Amgen's Repatha® Reduces Risk of Death in Patients at High Risk for a First Heart Attack or Stroke

THOMSON REUTERS
·
Aug 31

Abbott, Vistra, Unity, United, Nu: Insider Shockwave

TIPRANKS
·
Aug 29